- Home
- PTC vs INSM Comparison
PTC vs INSM Comparison
Compare PTC & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTC
- INSM
- Stock Information
- Founded
- PTC 1985
- INSM 1988
- Country
- PTC United States
- INSM United States
- Employees
- PTC N/A
- INSM N/A
- Industry
- PTC Computer Software: Prepackaged Software
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- PTC Technology
- INSM Health Care
- Exchange
- PTC Nasdaq
- INSM Nasdaq
- Market Cap
- PTC 24.3B
- INSM 29.0B
- IPO Year
- PTC 1989
- INSM 2000
- Fundamental
- Price
- PTC $203.66
- INSM $165.41
- Analyst Decision
- PTC Buy
- INSM Strong Buy
- Analyst Count
- PTC 13
- INSM 19
- Target Price
- PTC $209.77
- INSM $155.88
- AVG Volume (30 Days)
- PTC 718.5K
- INSM 2.2M
- Earning Date
- PTC 11-05-2025
- INSM 10-30-2025
- Dividend Yield
- PTC N/A
- INSM N/A
- EPS Growth
- PTC 73.27
- INSM N/A
- EPS
- PTC 4.25
- INSM N/A
- Revenue
- PTC $2,471,978,000.00
- INSM $398,105,000.00
- Revenue This Year
- PTC $14.08
- INSM $32.44
- Revenue Next Year
- PTC $7.51
- INSM $123.99
- P/E Ratio
- PTC $47.73
- INSM N/A
- Revenue Growth
- PTC 11.42
- INSM 21.15
- 52 Week Low
- PTC $133.38
- INSM $60.40
- 52 Week High
- PTC $219.69
- INSM $166.44
- Technical
- Relative Strength Index (RSI)
- PTC 49.99
- INSM 75.01
- Support Level
- PTC $197.09
- INSM $161.34
- Resistance Level
- PTC $204.56
- INSM $166.40
- Average True Range (ATR)
- PTC 3.49
- INSM 4.37
- MACD
- PTC 0.11
- INSM -0.03
- Stochastic Oscillator
- PTC 71.34
- INSM 95.95
About PTC PTC Inc.
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America and Europe.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.